This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
MYGN Stock Might Gain From SneakPeek Availability in Retail Stores
by Zacks Equity Research
Myriad Genetics announces the availability of SneakPeek - the first at-home early fetal sex test in Walmart, Walgreens and CVS stores nationwide.
QGEN Collaborates With McGill University Centre: Stock to Gain?
by Zacks Equity Research
QIAGEN joins forces with McGill University Centre for Microbiome Research to generate evidence-based knowledge for medicine and public health.
Expanding Global Market, NuVasive Benefits to Aid GMED Stock
by Zacks Equity Research
Globus Medical is seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
Alcon Q3 Earnings Top Estimates, Margins Up, Stock Gains in Afterhours
by Zacks Equity Research
ALC's performance is driven by robust demand for the company's innovative products, balanced geographic footprint and strong execution by the team.
INGN Stock Gains Following Q3 Earnings Beat, Adjusted Gross Margin Up
by Zacks Equity Research
Inogen's overall third-quarter 2024 results continue to gain from higher business-to-business sales.
ZBH Stock to Gain Support From Market Share Gains Amid Macro Issues
by Zacks Equity Research
Zimmer Biomet expects ROSA and Persona Cementless Knee to enhance its robotics and cementless market penetration to 50% to 60% range at a rapid pace.
Zacks.com featured highlights include Greenbrier, Walmart, Leidos, InterDigital and ResMed
by Zacks Equity Research
Greenbrier, Walmart, Leidos, InterDigital and ResMed have been highlighted in this Screen of The Week article.
OPK Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
Lower revenues from OPKO Health's products and services dampen its overall third-quarter 2024 performance.
AMN Stock Falls Despite Q3 Earnings & Revenues Beat, Margins Contract
by Zacks Equity Research
AMN Healthcare's dismal results in the majority of its segments led to a soft overall third-quarter performance.
PBH Q2 Earnings Match Estimates, Revenues Beat, Shares Rise
by Zacks Equity Research
Prestige Consumer Healthcare's second-quarter sales are impacted by the ongoing supply chain challenges in the Clear Eyes business.
5 Dividend Growth Stocks to Buy on Trump Win & Fed Rate Cut
by Sweta Killa
Trump's re-election and the Fed rate cut bring back the lure for dividend investing. We have highlighted five solid picks that promise growth.
CLOV Stock Declines Despite Q3 Earnings Beat, FY24 View Revised
by Zacks Equity Research
Clover Health's third-quarter 2024 results continue to benefit from the strength of its business model.
Veracyte Q3 Earnings Beat Estimates, 2024 Guidance Raised
by Zacks Equity Research
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.
BDX Stock Gains Following Q4 Earnings Beat and Higher Margins
by Zacks Equity Research
BD's overall topline in the fourth quarter of fiscal 2024 benefits from revenue growth in all segments.
Charles River's Q3 Earnings, Revenues Beat Estimates, Margins Fall
by Zacks Equity Research
CRL's organic revenue growth in the Manufacturing Solutions and RMS segments is more than offset by lower revenues in the DSA segment.
MASI Stock Gains Following Q3 Earnings Beat, Gross Margin Expands
by Zacks Equity Research
Masimo's third-quarter 2024 results continue to benefit from the strength in its Healthcare business.
Catalent's Stock Gains Despite Q1 Earnings Miss, Gross Margin Up
by Zacks Equity Research
CTLT's solid segmental results led to an encouraging fiscal first-quarter performance, driving share prices in after-hours trading.
Integra Q3 Earnings, Revenues Beat, Stock Up Despite Margin Pressure
by Zacks Equity Research
IART is optimistic about the fact that the shipping holds have largely been resolved within the third quarter.
HIMS Stock Gains Following In Line Q3 Earnings, Gross Margin Contracts
by Zacks Equity Research
Hims & Hers' both revenue channels witness strong revenue growth on the back of solid product demand in the third quarter.
INSP Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
Inspire Medical's both geographic segments witness strong revenue growth on the back of solid product demand in the third quarter.
Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
ResMed (RMD) possesses solid growth attributes, which could help it handily outperform the market.
Insulet Stock Gains From Expansion Strategies, Innovation
by Zacks Equity Research
PODD continues to drive increased awareness for Omnipod through its direct-to-consumer advertising campaign.
Here's Why ResMed (RMD) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
QGEN Stock Set to Gain From FDA's Clearance of QIAstat-Dx Mini Panel
by Zacks Equity Research
QIAGEN wins FDA clearance for the QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment.
BellRing Brands Inc. (BRBR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
BellRing Brands (BRBR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.